How psychoactive drugs act on serotonin (5‑HT2) brain receptors
Molecular Details of Psychoactive Drug Actions
Researchers are mapping how serotonin-targeting drugs attach to 5‑HT2 brain receptors to help create safer, more precise treatments for conditions like psychosis, autism, sleep problems, and obesity.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11298944 on NIH RePORTER |
What this research studies
If you or someone you care about has psychosis, autism, sleep problems, or obesity, this project aims to reveal the detailed 3D shapes of serotonin (5‑HT2) receptors when they bind different signaling partners and drugs. The team will use high-resolution structural methods combined with ultra-large computer docking of billions of compounds, plus targeted mutations and lab tests, to see which chemical features change receptor signaling. Those molecular blueprints will be used to spot drug features that steer effects toward benefit and away from side effects. Over time this could guide the design of safer, more selective medicines for people affected by serotonin-related conditions.
Who could benefit from this research
Good fit: This project does not enroll patients now, but it aims to benefit people with conditions tied to serotonin signaling such as psychosis, autism spectrum disorders, certain sleep disorders, and obesity.
Not a fit: People seeking immediate treatment or those with conditions unrelated to serotonin receptors are unlikely to gain direct, near-term benefit from this laboratory-focused work.
Why it matters
Potential benefit: Could enable the development of safer, more targeted medicines for serotonin-linked conditions with fewer side effects and better symptom control.
How similar studies have performed: Structural studies of other G protein-coupled receptors have successfully guided drug discovery, and applying similar techniques to 5‑HT2 receptors builds on that progress though the ultra-large docking approach is relatively new.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Roth, Bryan L. — Univ of North Carolina Chapel Hill
- Study coordinator: Roth, Bryan L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.